NDC 0078-0904

SIMBRINZA

Brinzolamide/brimonidine Tartrate

SIMBRINZA is a Ophthalmic Suspension/ Drops in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Brinzolamide; Brimonidine Tartrate.

Product ID0078-0904_9524ff62-7850-405a-9b93-311e8dde17ea
NDC0078-0904
Product TypeHuman Prescription Drug
Proprietary NameSIMBRINZA
Generic NameBrinzolamide/brimonidine Tartrate
Dosage FormSuspension/ Drops
Route of AdministrationOPHTHALMIC
Marketing Start Date2013-05-01
Marketing CategoryNDA / NDA
Application NumberNDA204251
Labeler NameNovartis Pharmaceuticals Corporation
Substance NameBRINZOLAMIDE; BRIMONIDINE TARTRATE
Active Ingredient Strength10 mg/mL; mg/mL
Pharm ClassesCarbonic Anhydrase Inhibitor [EPC],Carbonic Anhydrase Inhibitors [MoA],Adrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 0078-0904-38

1 BOTTLE in 1 CARTON (0078-0904-38) > 8 mL in 1 BOTTLE
Marketing Start Date2020-08-04
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "SIMBRINZA" or generic name "Brinzolamide/brimonidine Tartrate"

NDCBrand NameGeneric Name
0065-4147SIMBRINZAbrinzolamide/brimonidine tartrate
0078-0904SIMBRINZAbrinzolamide/brimonidine tartrate

Trademark Results [SIMBRINZA]

Mark Image

Registration | Serial
Company
Trademark
Application Date
SIMBRINZA
SIMBRINZA
85306875 4388553 Live/Registered
Novartis AG
2011-04-28

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.